ClinicalTrials.gg
CompletedNCT02800811Updated Jul 21, 2016

Safety, Tolerability, PK, PD, and Immunogenicity of Single and Multiple Ascending Intravenous Doses of FR104

A Phase 1 interventional study of FR104 and Placebo in Rheumatoid Arthritis and Complication of Transplant, sponsored by OSE Immunotherapeutics. Completed at 1 site in Belgium. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-07-21.

Sponsored by OSE Immunotherapeutics · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 189 studies in Arthritis, Rheumatoid with a site in Belgium — 10 open to participants now, 21 under way, 2 of them phase 3. Arthritis, Rheumatoid · Belgium.

Enrollment
132nd of 158
64 · median 291
Started
2015
with 9 others
Phase 1
9 of 189
3 open now
Registered
139th of 189
by date

Among the 189 studies in Arthritis, Rheumatoid with a site in Belgium, this one is the 132nd largest by enrollment of the 158 interventional ones that give a count, is one of 10 that started in 2015, is one of 9 in phase 1, and was the 139th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

10 of the 189 studies in Arthritis, Rheumatoid with a site in Belgium are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 189 studies in Arthritis, Rheumatoid with a site in Belgium, or all of them as a file.
02

Study summary

First-in-human, phase I, randomized, double-blind, placebo-controlled, single center study evaluating single and multiple ascending intravenous doses of FR104 in healthy subjects.

Read the detailed description

This study is a first-in-human, phase I, randomized, double-blind, placebo-controlled, single center study evaluating single and multiple ascending intravenous doses of FR104 in healthy subjects.

64 healthy male and female subjects are selected according to the inclusion and exclusion criteria, i.e., 50 subjects in Part 1 (SAD: 2 cohorts of 22 [Cohort A], 28 [Cohort B], respectively) and 14 subjects in Part 2 (MAD). The total duration of the study is 10 months.

All FR104 doses are administered intravenously by a slow infusion of at least 30 minutes. A staggered approach is observed within all dose levels. An interval of at least 14 days (last to first administration) is observed between all dose levels. Individual subjects on a same day of dosing are dosed at least 60 minutes apart.

03

Conditions studied

  • Rheumatoid Arthritis
  • Complication of Transplant

Keywords

  • FR104
  • CD28
  • immunomodulation
  • T regulatory cell
  • Pegylated monovalent anti-CD28 Fab antibody
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects meeting all of the following criteria are eligible to participate in this study:

  1. Male or female, aged 18 to 60 years, extremes includes;
  2. In good health condition [medically stable] as determined on the basis of medical history, vital signs, clinical laboratory testing, and general physical examination performed at screening; Note: a retest can be done in case of an out of range clinical laboratory test value that will determine a subject's eligibility. This retest is preferably to be done at an unscheduled visit. The result of the retest are considered for subject eligibility. If the retest is outside normal reference ranges, the subject are eligible for inclusion only if the investigator judges the abnormalities to be not .
  3. (ECG) within normal range, or showing no clinically relevant deviations, as judged by the investigator; Note: a retest can be done in case of an out of range ECG value that can determine a subject's eligibility.
  4. Weighs at least 50 kg and no more than 100 kg and has a (BMI) within normal range: 18.0≤BMI\<30.0 kg/m2;
  5. Negative urine test for selected drugs of abuse at screening;
  6. Negative alcohol breath test at screening;
  7. Female subject is or surgically sterile (having had a hysterectomy, bilateral oophorectomy, or tubal ligation);
  8. Female subject has a negative pregnancy test at screening;
  9. Non-vasectomized male subjects having a female partner of must agree to the use of an effective method of until 90 days after the last administration of study drug ;
  10. Male subject has to agree not to donate sperm until 90 days after the last administration of study drug;
  11. Willing to adhere to the prohibitions and restrictions specified in this protocol;
  12. Form (ICF) signed voluntarily before any study-related procedure is performed, indicating that the subject understands the purpose of and procedures required for the study and is willing to participate in the study;
  13. Subjects were to be EBV-positive as per positive IgG Epstein-Barr nuclear antigen (EBNA) test;
  14. Nonsmoker or light smoker, i.e., smokes maximal 5 cigarettes (or 3 cigars or 3 pipe-full) per day, and ability and willingness to refrain from smoking during confinement and ambulant visits in the clinical research center.

    For Part 1, Cohort B only:

  15. The subject did not undergo a KLH challenge.

Exclusion criteria

Exclusion Criteria:

Subjects meeting one or more of the following criteria are excluded from participation in this study:

  1. A history of any (as determined by the investigator) cardiac, endocrinology, hematology, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease or excluding non-melanoma skin cancer;
  2. A known allergy, , or intolerance to the study drug, or to any of its compounds;
  3. The subject has a history of severe allergic or anaphylactic reactions;
  4. The subject has a history of consuming more than 21 (14 for females) units of alcoholic beverages per week or has a history of alcoholism or drug/chemical/substance abuse within past 2 years prior to screening (Note: one unit = 330 mL of beer, 110 mL of wine or 28 mL of spirits);
  5. Evidence or history of any clinically significant infections within the past 3 months;
  6. History of or evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB) diagnosed by a positive QuantiFERON® TB-Gold In Tube test or a positive tuberculin skin test ("Mantoux") in case of a weak positive QuantiFERON® TB-Gold In Tube test;
  7. Subjects with known clinically relevant immunological disorders, or auto-immune disorders, (e.g., rheumatoid arthritis, lupus erythematosus, scleroderma, etc...);
  8. Subjects with a recent infection of EBV diagnosed by a positive IgM VCA;
  9. A positive hepatitis panel (including surface antigen [HBsAg] and anti- virus [HCV] antibodies [Abs]) or positive (HIV) antibody screens;
  10. The subject has a supine systolic blood pressure (SBP) \<90 or >160 mmHg and a diastolic blood pressure (DBP) \<50 or >90 mmHg, or pulse rate higher than 100 bpm, either at screening (blood pressure measurements taken after subject has been resting in a supine position for a minimum of 5 minutes); Note: a retest can be done in case of an out of range vital signs value that will determine a subject's eligibility. The result of the retest are considered for subject eligibility.
  11. The subject is pregnant or breastfeeding;
  12. The subject has received a vaccine within 60 days prior to study drug administration;
  13. The subject has received any systemic agent within 6 months prior to study drug administration;
  14. The subject has received any antibody or biologic medicinal product within 6 months prior to study drug administration;
  15. The subject has received any systemic within 2 months prior to study drug administration;
  16. Use of a prohibited therapy within 14 days prior to study drug administration;
  17. Receipt of any drug within 30 days or ten half-lives, whichever is longer, prior to the initial study drug administration;
  18. The subject is participating in another clinical trial or has participated in another dose group of the current trial;
  19. Had a significant blood loss (including blood donation [>500 mL]) or having had a transfusion of any blood product within the 60 days or donated plasma within 7 days prior to the initial study drug administration;
  20. A condition that, in the opinion of the investigator, could compromise the well-being of the subject or course of the study, or prevent the subject from meeting or performing any study requirements.
  21. Intent to visit regions where tuberculosis and mycosis are endemic during the period of 3 months after dosing (4 months after dosing for subjects in Cohort C) , i.e., deserts areas, Eastern Europe, Central and South America, Africa except Egypt, Russia, Asia, Indonesia.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Part 1: Cohort A, Group 1, FR104

    Dose: single 0.005 mg/kg.

    Drug: FR104

  • Experimental
    Part 1: Cohort A, Group 2, FR104

    Dose: single 0.05 mg/kg.

    Drug: FR104

  • Experimental
    Part 1: Cohort A, Group 3, FR104

    Dose: single 0.2 mg/kg.

    Drug: FR104

  • Experimental
    Part 1: Cohort A, Group 4, FR104

    Dose: single 0.5 mg/kg.

    Drug: FR104

  • Placebo comparator
    Part 1: Cohort A, placebo

    Placebo, single administration, double blind (1/4 healthy subject in group 1, 1/4 in group 2, 2/5 in group 3 and 2/5 in group 4).

    Drug: Placebo

  • Experimental
    Part 1: Cohort B, Group 7, FR104

    Dose: single 0.5 mg/kg. Healthy subject naïve to KLH and that will receive a KLH challenge.

    Drug: FR104

  • Experimental
    Part 1: Cohort B, Group 8, FR104

    Dose: single 0.2 mg/kg. Healthy subject naïve to KLH and that will receive a KLH challenge.

    Drug: FR104

  • Experimental
    Part 1: Cohort B, Group 9, FR104

    Dose: single 1.5 mg/kg. Healthy subject naïve to KLH and that will receive a KLH challenge.

    Drug: FR104

  • Experimental
    Part 1: Cohort B, Group 9 bis, FR104

    Dose: single 0.02 mg/kg group. Healthy subject naïve to KLH and that will receive a KLH challenge.

    Drug: FR104

  • Placebo comparator
    Part 1: Cohort B, placebo

    placebo, single administration, double-blind: healthy subjects naïve to KLH and that will receive a KLH challenge (2/5 in each group of cohort B)

    Drug: Placebo

  • Experimental
    Part 2: Group 10, FR104

    Dose: repeat, 0.2 mg/kg. Two administrations separated by an interval of 28 days.

    Drug: FR104

  • Experimental
    Part 2: Group 11, FR104

    Dose: repeat, 0.5 mg/kg. Two administrations separated by an interval of 28 days.

    Drug: FR104

  • Placebo comparator
    Part 2: placebo

    placebo, repeat, double-blind: 2/5 subjects in each group of Part 2. Two administrations separated by an interval of 28 days.

    Drug: Placebo

Interventions

  • DrugFR104

    GMP FR104 is provided to the site in extractable volume vials containing FR104. Appropriate Dilutions in Ringer's lactate solution is made on site.

  • DrugPlacebo

    The placebo injection contains the vehicle. For placebo dosing, vehicle is administered in accordance with the volume of study drug administered.

06

What researchers measure

Primary outcomes

  1. Type, incidence, severity, timing, seriousness and relatedness of treatment emergent adverse events, and abnormalities in laboratory parameters in healthy volunteers of FR104 compared to placebo after single (SAD) and two IV doses (MAD).

    During each treatment period, subjects will be housed and monitored at the study center from the day before dosing (Day-1) until Day 5. Thenafter, each subject will attend ambulatory visit at predefined days until day 113.

    Time frame: 4 months

Secondary outcomes

  1. Area under the concentration time curve to last quantifiable concentration [AUC (0-T)] after single and two repeat iv administrations of FR104

    During each treatment period, subjects will be housed and monitored at the study center from the day before dosing (Day-1) until Day 5. Thenafter, each subject will attend ambulatory visit at predefined days until day 113.

    Time frame: 4 months

  2. Terminal half-life (T1/2) of FR104 after single and two repeat iv administrations

    During each treatment period, subjects will be housed and monitored at the study center from the day before dosing (Day-1) until Day 5. Thenafter, each subject will attend ambulatory visit at predefined days until day 113.

    Time frame: 4 months

  3. Durations of 100%, 50% and 20% CD28 receptor blocade after single and two repeat iv administrations of FR104

    During each treatment period, subjects will be housed and monitored at the study center from the day before dosing (Day-1) until Day 5. Thenafter, each subject will attend ambulatory visit at predefined days until day 113.

    Time frame: 4 months

  4. Incidence of antidrug antibodies (ADA) and neutralizing antibodies (NAb) after single and two repeat iv administrations of FR104

    During each treatment period, subjects will be housed and monitored at the study center from the day before dosing (Day-1) until Day 5. Thenafter, each subject will attend ambulatory visit at predefined days until day 113.

    Time frame: 4 months

  5. Type, incidence, severity, timing, seriousness and relatedness of abnormal cytokine levels after single and two repeat iv administrations of FR104

    During each treatment period, subjects will be housed and monitored at the study center from the day before dosing (Day-1) until Day 5. Thenafter, each subject will attend ambulatory visit at predefined days until day 113.

    Time frame: 4 months

Other outcomes

  1. To explore through study completion the immune activity (whole blood TruCulture® assay) of FR104 (Part 1 and 2).

    During each treatment period, subjects will be housed and monitored at the study center from the day before dosing (Day-1) until Day 5. Thenafter, each subject will attend ambulatory visit at predefined days until day 113.

    Time frame: 4 months

  2. To explore through study completion the effect of FR104 on the response to keyhole limpet hemocyanin (KLH) challenge (Part 1, Cohort B).

    During each treatment period, subjects will be housed and monitored at the study center from the day before dosing (Day-1) until Day 5. Thenafter, each subject will attend ambulatory visit at predefined days until day 113.

    Time frame: 4 months

  3. To evaluate through study completion the effect of FR104 on lymphocytes subsets (Part 1: 0.2 and 0.5 mg/kg doses [Cohort A], 2 doses up to 5 (or lower than 0.5) mg/kg [Cohort B, Groups 9 and 9 bis])

    During each treatment period, subjects will be housed and monitored at the study center from the day before dosing (Day-1) until Day 5. Thenafter, each subject will attend ambulatory visit at predefined days until day 113.

    Time frame: 4 months

  4. Apparent clearance (CL/F) after single and two repeat iv administrations of FR104

    During each treatment period, subjects will be housed and monitored at the study center from the day before dosing (Day-1) until Day 5. Thenafter, each subject will attend ambulatory visit at predefined days until day 113.

    Time frame: 4 months

  5. Apparent volume of distribution (Vz/F) after single and two repeat iv administrations of FR104

    During each treatment period, subjects will be housed and monitored at the study center from the day before dosing (Day-1) until Day 5. Thenafter, each subject will attend ambulatory visit at predefined days until day 113.

    Time frame: 4 months

07

Study locations

1 site
  • SGS Antwerpen
    Antwerpen, Belgium
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2015, a primary completion of Jun 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2016
First posted
Jun 15, 2016
Start
Apr 2015
Primary completionActual
Jun 2016
CompletionActual
Jul 2016
Last update
Jul 21, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02800811
Lead sponsor
OSE Immunotherapeutics
Responsible party
Sponsor
First posted
Jun 15, 2016
Start date
Apr 2015
Primary completion
Jun 2016
Completion
Jul 2016
Last update
Jul 21, 2016

Study contacts

Steven Ramael
principal investigator · SGS Antwerpen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegrizeprument

Start the discussion